Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.
A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
An innovative new technique that encourages cancer cells in the kidneys to self-destruct could revolutionize the treatment of the disease, a new study in the journal Pharmaceutics reports.
Many patients with cancer receive immune checkpoint inhibitors that strengthen their immune response against tumor cells. While the medications can be life-saving, they can also cause potentially life-threatening side effects in internal organs.
Tumors consume glucose at high rates, but a team of Vanderbilt researchers has discovered that cancer cells themselves are not the culprit, upending models of cancer metabolism that have been developed and refined over the last 100 years.
The evolution of the refined human immune system has turned into an effective defense system against several diseases, including cancer.
A team of researchers have plotted the genes that enable cancer cells to avoid being destroyed by the immune system.
An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.
Treatments for kidney cancer have improved considerably over the past few decades. In 1988, when Memorial Sloan Kettering oncologist Robert Motzer started researching the disease, the average survival was less than one year.
Physicians at City of Hope, working in collaboration with scientists at Translational Genomics Research Institute (TGen), have found that greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on Food and Drug Administration-approved immunotherapy regimens.
Metastasis - the development of tumor growth at a secondary site - is responsible for the majority of cancer-related deaths.
A highly sensitive blood test has been found to accurately diagnose and classify different types of brain tumors, resulting in more accurate diagnosis.
A wholistic tumor sampling method that more accurately detects genetic alterations in tumors, which are critical in allowing treatment to be personalized to each and every patient, has been developed by researchers from the Crick, Roche and The Royal Marsden NHS Foundation Trust and published in Cell Reports.